Relevant bibliographies by topics / Antitubercular treatment

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Antitubercular treatment'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antitubercular treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antitubercular treatment"

1

Zitko, Jan, and Martin Doležal. "Old Drugs and New Targets as an Outlook for the Treatment of Tuberculosis." Current Medicinal Chemistry 25, no. 38 (2019): 5142–67. http://dx.doi.org/10.2174/0929867324666170920154325.

Full text
Abstract:
Background: Despite of the globally positive trends in the epidemiology of tuberculosis, the increasing rates of drug-resistant strains are urging to introduce new antituberculars into clinical practice. Development of a new chemical entity from hit to marketed drug is an extremely time and resources consuming process with uncertain outcome. Repurposing of clinically used drugs can be a cheaper alternative to develop new drugs effective in the treatment of tuberculosis. Objective: To extract the latest information on new mechanisms of action described or proposed for clinically used antituberc
APA, Harvard, Vancouver, ISO, and other styles
2

Ayushi, Praveen Jaiswal Mr., Shaneza Aman Ms., Ashok Kumar Sharma Mr., Purushottam Prajapati Mr., and Mehul Kumar Choudhary Mr. "A NEW DRUG- VXc-486 TUBERCULOSIS TREATMENT: A REVIEW." International Journal of Current Pharmaceutical Review and Research 13, no. 2 (2021): 24–27. https://doi.org/10.5281/zenodo.12667297.

Full text
Abstract:
Tuberculosis (TB) is a communicable disorder from time to time because of themicroorganism mycobacterium tuberculosis (MTB). Antitubercular agent acts as inhibitingthe growth of Mycobacterium tuberculosis. Antitubercular agents specifically act with the aidof using inhibit the growth of microorganism with the aid of using cell wall synthesisinhibition. VXc-486 is a powerful antitubercular drug belonging with aminobenzimidazolecategory. The novel aminobenzimidazole, VXc-486, which targets gyrase B, potently inhibitsa couple of drug-sensitive isolates and drug-resistant isolates of Mycobacterium
APA, Harvard, Vancouver, ISO, and other styles
3

Dion Pratama Puja, Putu. "Treatment of Pulmonary TB Patients on Antitubercular Medications with Transaminitis." International Journal of Science and Research (IJSR) 11, no. 5 (2022): 725–28. http://dx.doi.org/10.21275/sr22505082555.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chaudhary, Meenakshi. "Butterfly pattern hypopigmentation with antitubercular treatment." International Journal of Basic & Clinical Pharmacology 3, no. 2 (2014): 1. http://dx.doi.org/10.5455/2319-2003.ijbcp20140434.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Likhitha, B. K., Shreeshail Anjutagi, Keertivardhan D. Kulkarni, and Madhav Mahawar. "Challenges faced during antitubercular therapy." BLDE University Journal of Health Sciences 9, no. 2 (2024): 184–86. https://doi.org/10.4103/bjhs.bjhs_131_24.

Full text
Abstract:
Abstract This case report discusses regarding a 48-year-old male with drug-sensitive tuberculosis (TB) and alcoholic liver disease, who experienced significant side effects during antitubercular therapy. The patient presented with peripheral neuropathy, deranged liver function, elevated uric acid levels, gastritis, and psychological distress during the treatment period. Modifications included the change of regimen and the symptomatic treatment of the associated side effects with regular liver function monitoring. Comprehensive patient education and counseling were provided to enhance adherence
APA, Harvard, Vancouver, ISO, and other styles
6

Olga Mykolaivna Shvets, Olga Stanislavna Shevchenko, and Hanna Leonidivna Stepanenko. "INSULIN RESISTANCE IN DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS PATIENTS DURING THE FIRST MONTH OF ANTITUBERCULAR TREATMENT." International Academy Journal Web of Scholar 1, no. 8(38) (2019): 13–17. http://dx.doi.org/10.31435/rsglobal_wos/31082019/6650.

Full text
Abstract:

 
 
 The study was aimed to investigate insulin resistance development in drug-susceptible newly diagnosed pulmonary tuberculosis patients. Those patients who developed insulin resistance during the 30 days of antitubercular therapy have expressed metabolic changes, that may be associated with impaired liver function due to the toxic effects of antitubercular drugs.
 
 
APA, Harvard, Vancouver, ISO, and other styles
7

Kar, Sidhartha S., and Cinu A. Thomas. "Strategically Placed Trifluoromethyl Substituent in the Realm of Antitubercular Drug Design." Current Drug Therapy 14, no. 2 (2019): 114–23. http://dx.doi.org/10.2174/1574885513666180906101732.

Full text
Abstract:
Background:Fluorinated substituents have played, and continue to play an important role in antitubercular drug design. Nonetheless, previous works have indicated that organofluorines like –F, CF3, -OCF3, and CHF2 etc have been used to modulate the pharmacodynamic and pharmacokinetic behaviour of antitubercular agents. Among the fluorinated groups, trifluoromethyl (-CF3) substituent is a very familiar pharmacophore used widely in antitubercular research.Objective:This review assesses the development of selected trifluoromethyl group bearing antitubercular agents that are either in treatment or
APA, Harvard, Vancouver, ISO, and other styles
8

Yadav, Gulab S., Vinod K. Jangid, and Brij B. Mathur. "Study of various reasons for interruption of anti-tubercular treatment in patients of tuberculosis reporting to tertiary care center of west Rajasthan." International Journal of Research in Medical Sciences 7, no. 6 (2019): 2220. http://dx.doi.org/10.18203/2320-6012.ijrms20192542.

Full text
Abstract:
Background: Tuberculosis is a major cause of death in India. Premature cessation of treatment in tuberculosis patient is a leading cause for developing MDR (multidrug resistant tuberculosis) as well as a major threat to control programs. Despite the easy approach and free of cost, availability to antitubercular medicines the interruptions of the treatment are still on a high. So, we analyzed such various reasons leading to interrupt the antitubercular treatment.Methods: Total 150 patients who interrupted the antitubercular treatment, were interviewed with a predesigned questionnaire and the re
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Chungen, Yunxiang Tang, Zitai Sang, et al. "Discovery of napabucasin derivatives for the treatment of tuberculosis." MedChemComm 10, no. 9 (2019): 1635–40. http://dx.doi.org/10.1039/c9md00295b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Karthik, G. S., Kritika Sahay, Kiranmai Ismal, Swarnalata Gowrishankar, Nikita Sahay, and Manisha Sahay. "A Case Series of Bile Cast Nephropathy-induced Rapidly Progressive Renal Failure." Osmania Journal of Medical Research 1, no. 1 (2024): 25–28. http://dx.doi.org/10.4103/ojmr.ojmr_19_23.

Full text
Abstract:
Abstract A 45-year-old male presented to the hospital with symptoms of left inguinal swelling, which showed granulomatous adenitis on fine-needle aspiration cytology. He was diagnosed with tuberculous adenitis, for which he was started on antitubercular treatment. After 15 days of antitubercular treatment, the patient developed deranged renal parameters, with serum creatinine of 8.8 mg/dL while serum bilirubin rose to 7.4 mg/dL. The patient was oliguric and underwent four sessions of hemodialysis. Following this, a renal biopsy was done, which showed normal glomeruli with tubular casts that we
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antitubercular treatment"

1

Martins, Tatiana dos Reis. "Microencapsulation of antitubercular drugs in a matrix of partially hydrolyzed guar gum, for application in tuberculosis treatment." Master's thesis, Instituto de Tecnologia Química e Biológica António Xavier. Universidade Nova de Lisboa, 2015. http://hdl.handle.net/10362/43588.

Full text
Abstract:
Trabalho realizado na Universidade do Algarve<br>Tuberculosis (TB), despite being a completely curable disease, has reemerged due to drug resistance and deadly synergism with HIV infection, which limit the success of its management. Lung tuberculosis is the main manifestation of TB. Thus, exploring the inhalable route for a local delivery of antitubercular drugs seems a promising therapeutic approach. Partially hydrolyzed guar gum (PHGG) is a strong candidate as matrix material for antitubercular drug carriers. This is mainly due to its affinity for macrophages, the hosts of mycobacteria, whic
APA, Harvard, Vancouver, ISO, and other styles
2

Hoa, Nguyen Phuong. "Tuberculosis control in Vietnam : directly observed treatment, short-course (DOTS) - the role of information and education /." Stockholm, 2004. http://diss.kib.ki.se/2004/91-7140-088-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Adewumi, Olayinka Anthony. "Treatment outcomes in patients infected with multidrug resistant tuberculosis and in patients with multidrug resistant tuberculosis coinfected with human immunodeficiency virus at Brewelskloof Hospital." Thesis, University of the Western Cape, 2012. http://etd.uwc.ac.za/index.php?module=etd&action=viewtitle&id=gen8Srv25Nme4_8245_1375971752.

Full text
Abstract:
<p>Many studies have reported low cure rates for multidrug-resistant tuberculosis (MDRTB) patients and MDR-TB patients co-infected with human immunodeficiency virus (HIV). However, little is&nbsp<br>known about the effect of HIV infection and antiretroviral therapy on the treatment outcomes of MDR-TB in South Africa. Therefore, the objectives of the study are: to find out whether HIV infection&nbsp<br>and interactions between ARVs and second line anti-TB drugs have an impact on the following MDR-TB treatment outcomes: cure rate and treatment failure at Brewelskloof Hospital. MDR-TB&nbsp<br>pat
APA, Harvard, Vancouver, ISO, and other styles
4

Ren, Yuan. "The Plasma, Whole Blood and Intracellular Concentrations of Antiretroviral Agents in South African Children Receiving Combination Antiretroviral Therapy with and without Concomitant Antitubercular Treatment." Doctoral thesis, University of Cape Town, 2009. http://hdl.handle.net/11427/3297.

Full text
Abstract:
Background: Tuberculosis (TB) is the most common opportunistic infection in children with human immunodeficiency virus (HIV) infection in developing countries, and co-treatment for HIV infection and TB is frequently indicated. Efavirenz and lopinavir/ritonavir (ratio 1:1) as part of antiretroviral therapy are used in combination with rifampicin-based antitubercular treatment in South African TB/HIV co-infected children. Adult studies show that concomitant rifampicin significantly reduces efavirenz and lopinavir plasma concentrations. However, the pharmacokinetics (PK) of efavirenz and lopinavi
APA, Harvard, Vancouver, ISO, and other styles
5

Farr, Dylan C. "Design and Synthesis of Novel Glycolipid Therapeutics and Drug Delivery Systems Targeting Mycobacterium tuberculosis." Thesis, Griffith University, 2021. http://hdl.handle.net/10072/406985.

Full text
Abstract:
The development of novel medicinal agents is becoming increasingly important in solving several serious healthcare issues. Tuberculosis (TB) is among one of the world’s most serious health threats, especially in developing countries, and although treatment is available, current methods take 6 – 24 months. Prolonged treatment times often result in noncompliance and subsequently result in selection for drug resistance. As there are several multidrug resistant strains of Mycobacterium tuberculosis current treatment methods are proving inadequate, and it is becoming more and more essential to deve
APA, Harvard, Vancouver, ISO, and other styles
6

Danijela, Vukosav. "Karakteristike toka plućne tuberkuloze kod obolelih od šećerne bolesti." Phd thesis, Univerzitet u Novom Sadu, Medicinski fakultet u Novom Sadu, 2019. https://www.cris.uns.ac.rs/record.jsf?recordId=110192&source=NDLTD&language=en.

Full text
Abstract:
Uvod: Povezanost dijabetesa melitusa i&nbsp; tuberkuloze je odavno primećena i bila je predmet ispitivanja mnogih studija. Dijagnoza &scaron;ećerne bolesti pre otkrića insulina značila je smrtni ishod u roku od pet godina, a najče&scaron;ći uzrok smrti su bile infekcije, uključujući tuberkulozu. Poslednjih godina incidenca tuberkuloze je u padu, ali je i dalje prisutan značajan broj obolelih od tuberkuloze u zemljama u razvoju. Sa druge strane incidenca dijabetes melitusa je u porastu, pre svega zbog tendencije porasta broja gojaznih osoba. Procenjeno je da će prevalencija obolelih od dijabete
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antitubercular treatment"

1

Organization, World Health, ed. Treatment of tuberculosis: Guidelines for national programmes. World Health Organization, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

World Health Organization (WHO). Treatment of tuberculosis: Guidelines. 4th ed. World Health Organization, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

McHugh, Timothy D. Tuberculosis: Laboratory diagnosis and treatment strategies. CAB International, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Organization, World Health, ed. WHO model prescribing information: Drugs used in mycobacterial diseases. World Health Organization, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ernesto, Jaramillo, Stop TB Initiative (World Health Organization), Great Britain. Dept. for International Development., and United States. Agency for International Development., eds. Guidelines for the programmatic management of drug-resistant tuberculosis: [emergency update 2008]. World Health Organization, Stop TB Department, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ernesto, Jaramillo, Stop TB Initiative (World Health Organization), Great Britain. Dept. for International Development., and United States. Agency for International Development., eds. Guidelines for the programmatic management of drug-resistant tuberculosis: [emergency update 2008]. World Health Organization, Stop TB Department, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nguy, Shui. Drug-resistant tuberculosis: Causes, diagnosis, and treatments. Edited by K'ung Zhou. Nova Science Publishers, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Organization, World Health. Treatment of Tuberculosis: Guidelines for National Programmes. World Health Organization, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ahmad, Suhail, and Eiman Mokaddas. Tuberculosis and Multidrug-Resistant Tuberculosis: Epidemiology, Diagnosis, Resistance Mechanisms, Treatment Strategies and Novel Drugs. Nova Science Publishers, Incorporated, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Organization, World Health. WHO Model Prescribing Information. World Health Organization, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antitubercular treatment"

1

Ibrahim, Mariam, and Lucila Garcia-Contreras. "Preclinical Pharmacokinetics of Antitubercular Drugs." In Drug Delivery Systems for Tuberculosis Prevention and Treatment. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118943182.ch7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Buttini, Francesca, and Gaia Colombo. "Formulation Strategies for Antitubercular Drugs by Inhalation." In Drug Delivery Systems for Tuberculosis Prevention and Treatment. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118943182.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chauhan, Mrs Pooja. "Antitubercular Agents." In Edited Book of Pharmacology-III [According to Latest Syllabus of B. Pharm-VI Semester of Pharmacy Council of India]. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/nbennurphch9.

Full text
Abstract:
Antitubercular agents are medications used to treat tuberculosis (TB), a serious infectious disease caused by Mycobacterium tuberculosis. These agents are categorized into first-line and second-line drugs based on their efficacy, toxicity, and role in TB treatment regimens. First-line antitubercular drugs, such as isoniazid, rifampin, pyrazinamide, and ethambutol, are the cornerstone of TB therapy due to their high potency and relative safety. These drugs are usually administered in combination to prevent the development of drug resistance and to effectively eradicate the bacteria. Treatment t
APA, Harvard, Vancouver, ISO, and other styles
4

Prasad, Rajendra, and Nikhil Gupta. "Interaction between Antitubercular and Antiretroviral Drugs." In Clinical Tuberculosis: Diagnosis and Treatment. Jaypee Brothers Medical Publishers (P) Ltd., 2015. http://dx.doi.org/10.5005/jp/books/12549_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shilpi, Satish, Karan Joshi, Chetan Ram, et al. "Mucoadhesive polymeric nanocarriers for the treatment of tuberculosis." In Emerging Paradigms in Delivery Systems for Antitubercular Therapy. Elsevier, 2025. https://doi.org/10.1016/b978-0-443-24035-5.00008-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Srivastava, Nimisha, and Emamezi Samuel. "Recent gene therapy approaches for the treatment of tuberculosis." In Emerging Paradigms in Delivery Systems for Antitubercular Therapy. Elsevier, 2025. https://doi.org/10.1016/b978-0-443-24035-5.00009-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Singh, Manisha, Nagma Banjare, Abhay Singh Chauhan, and Prem N. Gupta. "Recent approaches for the treatment of multidrug resistance tuberculosis." In Emerging Paradigms in Delivery Systems for Antitubercular Therapy. Elsevier, 2025. https://doi.org/10.1016/b978-0-443-24035-5.00013-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Loharkar, Soham, Shashikanta Sahu, Shristi Arya, et al. "Role of metallic nanoparticles in the treatment of tuberculosis." In Emerging Paradigms in Delivery Systems for Antitubercular Therapy. Elsevier, 2025. https://doi.org/10.1016/b978-0-443-24035-5.00003-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Shrivastava, Priya, Laxmikant Gautam, and S. P. Vyas. "Role of carbon nanotubes for the treatment of tuberculosis." In Emerging Paradigms in Delivery Systems for Antitubercular Therapy. Elsevier, 2025. https://doi.org/10.1016/b978-0-443-24035-5.00006-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mazahir, Farhan, Prakash Kumar Sirvi, Londhe Sachin Bhimrao, Ramdas Mane, Shashi Kashyap, and Awesh K. Yadav. "Novel targets and drugs for the treatment of tuberculosis." In Emerging Paradigms in Delivery Systems for Antitubercular Therapy. Elsevier, 2025. https://doi.org/10.1016/b978-0-443-24035-5.00010-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antitubercular treatment"

1

Gabrovska, Nataliya, Kaloyan Gabrovski, Krasimir Minkin, Svetlana Velizarova, and Petko Minchev. "Severe thoracic tuberculous spondylitis (Pott’s disease) in a 4-year old child treated with antitubercular treatment and surgical decompression, pedicle screw instrumentation and vertebral body reconstruction - a case report." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2755.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antitubercular treatment' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography